We're #hiring a new Office Manager / Executive Assistant. Apply today or share this post with your network.
Bioqube Ventures
Venture Capital and Private Equity Principals
“The greatest investment we can ever make is to invest our life in the life of someone else.”
About us
Bioqube Ventures, founded in 2015 by Debora Dumont and Nico Vandervelpen, is a specialist life sciences investment firm based in Europe and US with a global footprint. We source, finance and develop innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors. Bioqube Ventures is dedicated to funding therapeutic innovations: … a life sciences venture capital fund – dedicated to advancing exciting science in European and US ecosystems to breakthrough therapies for patients. … a fit-for-purpose dual investment model – besides more classical investments in investment rounds, we have special attention for venture creation projects that require additional experiments prior to creating new ventures. With our in-house factory model we are able to translate exciting science into trailblazing companies. … a hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths. We believe in putting our expertise at work where it matters.
- Website
-
http://www.bioqubeventures.com
External link for Bioqube Ventures
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 2-10 employees
- Headquarters
- Brussels
- Type
- Privately Held
- Founded
- 2015
Locations
-
Primary
Get directions
Brussels, BE
Employees at Bioqube Ventures
Updates
-
Bioqube Ventures is thrilled to announce the unveiling of Spica Therapeutics today, and the addition of James Rush as CEO and Jim Van heusden as Independent Chairman of the Board. With its unique macrophage fingerprinting technology, Spica is identifying and advancing innovative macrophage-subset targeted therapies that can redefine the treatment paradigm for patients across multiple disease areas. Stay tuned for the exciting progress of Spica Therapeutics via their page below! #venturecapital #lifesciences #biotech #macrophagebiology Debora Dumont Alexander Demoulin
We are excited to announce the unstealthing of Spica Therapeutics with the backing of Bioqube Ventures. Spica is pioneering novel macrophage-targeted therapeutics to address the unmet needs of patients across multiple disease areas. Follow our page for more updates as we advance our therapies towards the clinic. Read our full press release below or visit our website for more information: www.spicatx.com #SpicaTherapeutics #biotech #lifesciences
-
Fellowship Career Opportunity: are you a scientist eager to learn more about venture capital in biotech? Then check out our 6-month Fellowship program at Bioqube below #vc #biotech #fellowship
-
Great to see our portfolio company Commit Biologics recognised by Labiotech.eu as one of the exciting biotechs to keep an eye out for in Europe! #healthcare #lifesciences #venturecapital
📣 Commit Biologics Bio has been recognised as one of 'Europe’s rising biotech stars: 10 startups to watch in 2024' by @Labiotech.eu! Since emerging from stealth in May this year, backed by €16m seed financing from Bioqube Ventures and Novo Holdings, we have been working to advance our ‘BiCE’ (Bispecific Complement Engaging) platform to transform the treatment of #cancer and #autoimmune disease. We are just getting started! Read the full article here: https://bitly.cx/zBhV
-
Exciting news from our portfolio: Bicara Therapeutics has announced the successful raise of $362 million in their upsized IPO. Kudos to Claire Mazumdar, Ryan Cohlhepp, Ivan Hyep and the team for their commitment to advance Bicara's innovative bifunctional therapy ficerafusp alfa with the potential to transform treatment outcomes for patients with solid tumors, including head and neck cancers. #bioqubeventures #healthcare #biotech #venturecapital #nasdaq https://lnkd.in/eNGgtmQx
-
-
Bioqube Ventures is pleased to welcome CatalYm GmbH to its portfolio, co-leading a $150M financing with Canaan alongside new investors Omega Funds, Forbion and Gilde Healthcare and with the support of existing investors.
-
-
We are pleased to announce the launch of Commit Biologics. A testament to our venture build strategy co-powered by Novo Holdings. #biotech #investment
-
-
Bioqube Ventures reposted this
Bioqube Ventures is pleased to welcome SynOx Therapeutics to its portfolio, co-leading a $75M Series B alongside existing investors Forbion and HealthCap. The proceeds will be used to generate registrational Phase 3 clinical and CMC data for emactuzumab, SynOx’s potentially best-in-class CSF-1R inhibiting monoclonal antibody for the treatment of Tenosynovial Giant Cell Tumours. #lifesciences #biopharma #oncology #investment https://lnkd.in/dHrb-uMN
-
-
Bioqube Ventures is pleased to welcome SynOx Therapeutics to its portfolio, co-leading a $75M Series B alongside existing investors Forbion and HealthCap. The proceeds will be used to generate registrational Phase 3 clinical and CMC data for emactuzumab, SynOx’s potentially best-in-class CSF-1R inhibiting monoclonal antibody for the treatment of Tenosynovial Giant Cell Tumours. #lifesciences #biopharma #oncology #investment https://lnkd.in/dHrb-uMN
-